- Conditions
- Irvine-Gass Syndrome
- Interventions
- Aflibercept
- Drug
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 1,620
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Retinal Vascular Disease
- Interventions
- Swept-Source Optical Coherence Tomography
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy
- Interventions
- ASP2020
- Drug
- Lead sponsor
- Astellas Institute for Regenerative Medicine
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Southaven, Mississippi • Cincinnati, Ohio + 1 more
- Conditions
- Neovascular (Wet) Age-related Macular Degeneration
- Interventions
- SKG0106
- Genetic
- Lead sponsor
- Skyline Therapeutics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Katy, Texas • Norfolk, Virginia
- Conditions
- Dry Age-Related Macular Degeneration, Geographic Atrophy
- Interventions
- iPSC-derived RPE/PLGA transplantation
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 55 Years to 95 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Bethesda, Maryland
- Conditions
- Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Childhood Hepatoblastoma, Childhood Synovial Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adrenocortical Carcinoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive, Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Retinoblastoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors
- Interventions
- cixutumumab, laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 7 Months to 30 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 93
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 78 more
- Conditions
- Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Vision Disorders, Sensation Disorders, Neurologic Manifestations, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Retinal Disease
- Interventions
- QR-110
- Drug
- Lead sponsor
- Laboratoires Thea
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa • Philadelphia, Pennsylvania
- Conditions
- Schizophrenia, Bipolar I Disorder
- Interventions
- ERG assessment (RSPA)
- Device
- Lead sponsor
- diaMentis Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2026
- U.S. locations
- 11
- States / cities
- Garden Grove, California • Lemon Grove, California • Torrance, California + 8 more
- Conditions
- Diabetes, Diabetic Retinopathy
- Interventions
- DVS supplementation
- Dietary Supplement
- Lead sponsor
- ZeaVision, LLC
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Pomona, California • Tahlequah, Oklahoma
- Conditions
- Retinopathy of Prematurity
- Interventions
- Goggles, Ambient Light Reduction
- Device · Procedure
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Up to 1 Day
- Timeline
- Started 1995
- U.S. locations
- 3
- States / cities
- Buffalo, New York • Dallas, Texas • San Antonio, Texas
- Conditions
- Geographic Atrophy
- Interventions
- JNJ-81201887, Prednisone, Placebo, Triamcinolone, Sham Procedure
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 79
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 66 more
- Conditions
- Cytomegalovirus Retinitis, HIV Infections
- Interventions
- Valganciclovir, Ganciclovir
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 14 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2002
- U.S. locations
- 15
- States / cities
- Irvine, California • La Jolla, California • San Diego, California + 8 more
- Conditions
- Retinopathy of Prematurity (ROP)
- Interventions
- rhIGF-1/rhIGFBP-3
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 40 Weeks to 108 Weeks
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 4
- States / cities
- Mobile, Alabama • Greenville, North Carolina • Oklahoma City, Oklahoma + 1 more
- Conditions
- Leber Congenital Amaurosis
- Interventions
- rAAV2-CB-hRPE65
- Biological
- Lead sponsor
- Beacon Therapeutics
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 2
- States / cities
- Worcester, Massachusetts • Portland, Oregon
- Conditions
- Age-Related Macular Degeneration
- Interventions
- SF0166 Topical Ophthalmic Solution
- Drug
- Lead sponsor
- OcuTerra Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Fullerton, California • Mountain View, California + 9 more
- Conditions
- Exudative Age-Related Macular Degeneration
- Interventions
- LHA510 ophthalmic suspension, LHA510 vehicle, Ranibizumab ophthalmic solution
- Drug
- Lead sponsor
- Alcon, a Novartis Company
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Retinal Disease, Macular Degeneration, Hereditary Retinal Dystrophy, Optic Nerve Disease, Glaucoma
- Interventions
- RB (Retrobulbar), ST (Subtenon), IV (Intravenous), IVIT (Intravitreal), IO (Intraocular)
- Procedure
- Lead sponsor
- MD Stem Cells
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- Westport, Connecticut
- Conditions
- Retinitis Pigmentosa, Leber Congenital Amaurosis
- Interventions
- OCU400 Low Dose, OCU400 Med Dose, OCU400 High Dose, OCU400 Second Eye Dosing
- Drug
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • La Jolla, California • Miami, Florida + 4 more
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, Multiple Sclerosis, Huntington Disease, Lewy Body Dementia, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis (ALS), APOE-4 Positive, Traumatic Brain Injury, Concussion, Post-Traumatic Stress Disorder, Down Syndrome, Neuro-Degenerative Disease, Normal Cognition
- Interventions
- Retinal and Choroidal Imaging
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy
- Interventions
- Sirolimus
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 56 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pseudophakic Cystoid Macular Edema,, Diabetic Macular Edema
- Interventions
- Dexamethasone Implant
- Drug
- Lead sponsor
- Northern California Retina Vitreous Associates
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Mountain View, California
- Conditions
- Neovascular Age-related Macular Degeneration, Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Diabetic Macular Edema
- Interventions
- AngioVue SD-OCT
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Age Related Macular Degeneration
- Interventions
- ranibizumab, dexamethasone and verteporfin, Ranibizumab
- Drug
- Lead sponsor
- Bay Area Retina Associates
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 4
- States / cities
- Castro Valley, California • Walnut Creek, California • Riverdale, Georgia + 1 more
- Conditions
- Cystoid Macular Edema
- Interventions
- Bromfenac (Xibrom), Refresh Plus
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland